Protein expression and gene amplification of epidermal growth factor receptor in non:small cell lung cancer: correlation with chemoresponse to gefitinib therapy: P1-180

نویسندگان

  • Sung W. 1 Cho Deog G. 1 Ahn Myeong I. 1 Kim Chi H. 1 Cho Kyu Kim
  • Hoon Kim
چکیده

Copyright © 2007 by the International Association for the Study of Lung Cancer S808 Coexistence of MALT lymphoma with carcinomas was seen primarly in gastric lesions associated with H. Pylori infections. To our knowledge only one case was reported with synchronous pulmonary adenocarcinoma and MALT type extranodal marginal zone lymphoma. Case Report: A 49 years old male presented with back pain, weight loss and fatique. Chest x-ray revealed an increased density suggesting a mass localized to superior zone of left lung. Systemic radiologic examination of the patient did not reveal any other mass lesion. Endoscopic examination of upper gastrointestinal system revealed gastric ulcer. The biopsy taken from the stomach and duodenum showed MALT lymphoma in both locations. He underwent an exploratory chest operation, during which a mass lesion comletely invading thorasic outlet and a second mass lesion located in apical segment of left upper lobe, seperated from the first mass by a thickened pleura were noted. A frozen section diagnoses of malignant neoplasm was given for the mass lesion invading thorasic outlet. Therefore, this mass was exsized along with wedge resection of the second apical lung lesion. The exsized first mass measured 5x4x0,7 cm, it was hard and gray to brown colored. The wedge resection covered with visceral pleura measured 8x5,5x 2cm and contained an infiltrative hard, grayish white mass of 2 cm diameter without pleural involvement.These two tumors,one of which was primarily localized in pleura with limited extension into the lung parenchyma and the other mainly localized in the lung parenchyma had different morphologic and immune phenotypic features. Light microscopy of the tumor involving mainly pleura showed a malignant epithelial tumor with mainly diffuse patern with focal papillary areas. The differential diagnoses of this tumor included primary or metastatic adenocarcinoma and epithelial mesothelioma. Mucicarmine stain was negative while PAS and D-PAS stains were positive in some tumor cells. Tumor cells were pankeratin and vimentin positive, TTF-1, CK7, CK 5/6, CK20, CEA, calretinin, NSE, synaptophysin and chromogranin negative. There was focal CD15 positivity. Although CK7 and TTF-1 were negative, these morphologic, histochemical and immunohistochemical features suggested that this tumor might represent an undifferentiated large cell or poorly differentiated pulmonary adenocarcinoma. The second tumor localized in lung parenchyma was well differentiated adenocarcinoma with mucicarmine positive intracytoplasmic mucine secretion. It had CK7, TTF-1 positive and vimentin, CK 5/6 and CK20 negative immunophenotype. This tumor was intimately associated with diffuse neoplastic lymphocytic infiltration. Neoplastic lymphocytic cells had a monocytoid appearance with formation of occasional lymphoepithelial lesions. Lymphocytic tumor cells CD20 positive, CD5, CD10, CD23, CD3 and cyclinD1 negative immunophenotype. Because of these features, a diagnoses of MALT lymphoma was given. To the best of our knowledge our case is the first one that presented with two different lung carcinomas which had different morphologic and immunophenotypic features, one of which was associated with multisystemic (lung, stomach,duodenum) extranodal marginal zone lymphoma of MALT type. P1-179 Pathology Posters, Mon, Sept 3

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Assessment of epidermal growth factor receptor status in glioblastomas

Objective(s): Our previous study showed that a newly designed tracer radioiodinated 6-(3-morpholinopropoxy)-7-ethoxy-4-(3'-iodophenoxy)quinazoline ([125I]PYK) is promising for the evaluation of the epidermal growth factor receptor (EGFR) status and prediction of gefitinib treatment of non-small cell lung cancer. EGFR is over-expressed and mutated also in glioblastoma. In the present study, the ...

متن کامل

Expression of Epidermal Growth Factor Receptor and the association with Demographic and Prognostic Factors in Patients with Non-small Cell Lung Cancer

Introduction: Growth, proliferation, survival, and differentiation are the prominent characteristics of cells, which are affected by cancer. Epidermal growth factor receptor (EGFR) plays a pivotal role in the effective control of these features. Given the significance of EGFR signaling pathway in non-small cell lung cancer (NSCLC), EGFR expression is influential on these cell characteristics. I...

متن کامل

The Relationship Between Fibroblastic Growth Factor Receptor-1 (FGFR1) Gene Amplification in Triple Negative Breast Carcinomas and Clinicopathological Prognostic Factors

Background & Objective: In Triple-Negative Breast Cancers (TNBCs), estrogen receptor (ER), progesterone receptor (PR) and HER2/neu genes are not expressed. Fibroblastic Growth Factor Receptor-1 (FGFR1) gene product is a protein that acts as a receptor of thyrosin kinase. It plays a role in the proliferation, differentiation, and migration of malignant cells. The objective was t...

متن کامل

Evaluation of the epidermal growth factor receptor gene mutation and copy number in non-small cell lung cancer with gefitinib therapy.

Several studies have suggested that epidermal growth factor receptor (EGFR) gene mutation, EGFR gene amplification, and some other biomarkers may be predictors of gefitinib sensitivity. We analyzed EGFR mutation and EGFR copy number in 22 gefitinib-treated non-small cell lung cancer (NSCLC) cases and their relation to the survival of patients. We also studied 143 gefitinib-naïve Japanese NSCLC ...

متن کامل

Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells.

PURPOSE The epidermal growth factor receptor (EGFR) inhibitor gefitinib (Iressa) has shown antitumor activity in clinical trials against cancers, such as non-small cell lung cancer and head and neck squamous cell carcinoma (HNSCC). Research on non-small cell lung cancer has elucidated factors that may predict response to gefitinib. Less is known about molecular markers that may predict response...

متن کامل

Discrepancy between the Clinical Image and Pathological Findings of Non-Small Cell Lung Cancer Harboring an Epidermal Growth Factor Receptor Gene Mutation That Was Surgically Resected after Gefitinib Treatment

We herein describe a discrepancy between the clinical image and pathological findings in a non-small cell lung cancer patient with an epidermal growth factor receptor (EGFR) mutation who underwent surgical resection after gefitinib treatment. The patient was a 66-year-old female with c-stage IIIA lung adenocarcinoma harboring an EGFR gene mutation; she was surgically treated after receiving gef...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:

دوره   شماره 

صفحات  -

تاریخ انتشار 2015